Decoding DEN-Induced Hepatocellular Carcinoma: Models, Mechanisms, and Ameliorative Strategies in Preclinical Research
Abstract
Objective: This review focuses specifically on the DEN-induced hepatocellular carcinoma model, with the objectives are to describing the establishment and characterisation of the DEN model, delineating the underlying molecular and cellular mechanisms driving DEN-induced hepatocarcinogenesis, and exploring various ameliorative treatment strategies investigated, including natural products and AgNPs, along with their proposed mechanisms of action. The review also discusses the translational relevance and limitations of the DEN model and outlines future directions in preclinical HCC research aiming to improve therapeutic outcomes.
Data sources: DEN, HCC, and hepatocarcinogenesis were among the search terms used to search databases such as PubMed, Google Scholar, and ScienceDirect. After screening abstracts and titles, conference proceedings and commentary were not included. 95 articles and book chapters were included in the final analysis out of 137 sources.
Summary: Future preclinical HCC studies employing DEN models will concentrate on overcoming constraints by combining therapies, targeting tumour heterogeneity, and leveraging enhanced drug delivery technologies, dietary restrictions, tumor microenvironment, and multi-omics approaches. Treatment results are improved by the focused, low-toxicity administration of anti-HCC medicines made possible by nanoparticles. Multi-omics technology integration can reveal new therapeutic targets, biomarkers, and mechanisms influencing the course of HCC and the effectiveness of treatment.
Conclusion: Because it mimics important aspects of actual HCC, the DEN-induced HCC model has proven essential in studying the course of liver cancer and testing treatments. The model is nevertheless crucial for investigating therapies, particularly in light of developments in omics and nanotechnology that are bringing preclinical findings closer to clinical use.
Keywords: DEN (diethylnitrosamine), HCC (hepatocellular carcinoma), CCl4 (carbon tetrachloride), Hepatocarcinogenesis, AgNPs.
Keywords:
DEN (diethylnitrosamine), HCC (hepatocellular carcinoma), CCl4 (carbon tetrachloride), Hepatocarcinogenesis , AgNPsDOI
https://doi.org/10.22270/jddt.v15i9.7367References
1. Nakayama J, Gong Z. Transgenic zebrafish for modeling hepatocellular carcinoma. MedComm. 2020;1(2):140-156. https://doi.org/10.1002/mco2.29 PMid:34766114 PMCid:PMC8491243
2. Nahon P, Allaire M, Nault J-C, Paradis V. Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma. Hepatic Oncol. 2020;7(4). https://doi.org/10.2217/hep-2020-0017 PMid:33680428 PMCid:PMC7907968
3. Song X-J, Ma C-H. Mechanisms and immunotherapies of HBV- and NAFLD-related hepatocellular carcinoma. Hepatoma Res. 2020. https://doi.org/10.20517/2394-5079.2020.05
4. Huang X, Wan F, Ma L, et al. Investigation of copper-cysteamine nanoparticles as a new photosensitizer for anti-hepatocellular carcinoma. Cancer Biol Ther. 2019;20(6):812-825. https://doi.org/10.1080/15384047.2018.1564568 PMid:30727796 PMCid:PMC6606015
5. Lencioni R, Braet F. Novel transarterial biomimetic-based nanoparticles for the treatment of hepatocellular carcinoma. Gastroenterology. 2016;150(2):312-314. https://doi.org/10.1053/j.gastro.2015.12.022 PMid:26710988
6. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364-378. https://doi.org/10.1016/j.ejphar.2014.07.025 PMid:25058905 PMCid:PMC4146684
7. Matsuda Y, Wakai T, Kubota M, et al. Sorafenib-inhibited signaling: emerging evidence of RAF independent pathways as potential therapeutic targets in hepatocellular carcinoma. InTech eBooks. 2013. https://doi.org/10.5772/55201
8. Shankaraiah RC, Gramantieri L, Fornari F, et al. Animal models of hepatocellular carcinoma prevention. Cancers. 2019;11(11):1792. https://doi.org/10.3390/cancers11111792 PMid:31739536 PMCid:PMC6895981
9. Yoon SK. Molecular mechanism of hepatocellular carcinoma. Hepatoma Res. 2018;4(8):42. https://doi.org/10.20517/2394-5079.2018.23
10. Uehara T, Pogribny IP, Rusyn I. The DEN and CCl4‐induced mouse model of fibrosis and inflammation‐associated hepatocellular carcinoma. Curr Protoc Pharmacol. 2014;66(1). https://doi.org/10.1002/0471141755.ph1430s66 PMid:25181010 PMCid:PMC4214366
11. Merle P, Trepo C. Molecular mechanisms underlying hepatocellular carcinoma. Viruses. 2009;1(3):852-872. https://doi.org/10.3390/v1030852 PMid:21994573 PMCid:PMC3185529
12. Sarcognato S, García‐Lezana T, Villanueva A. Mechanisms of action of drugs effective in hepatocellular carcinoma. Clin Liver Dis. 2019;14(2):62-65. https://doi.org/10.1002/cld.810 PMid:31508222 PMCid:PMC6726381
13. Rajesh Y, Sarkar D. Molecular mechanisms regulating obesity-associated hepatocellular carcinoma. Cancers. 2020;12(5):1290. https://doi.org/10.3390/cancers12051290 PMid:32443737 PMCid:PMC7281233
14. Zheng W, Deng M, Gong J. The molecular mechanism on the association of diabetes mellitus with hepatocellular carcinoma. Int Surg J. 2020;8(1):436. https://doi.org/10.18203/2349-2902.isj20205921
15. Xiong XX, Qiu XY, Hu DX, Chen XQ. Advances in hypoxia-mediated mechanisms in hepatocellular carcinoma. Mol Pharmacol. 2017;92(3):246-255. https://doi.org/10.1124/mol.116.107706 PMid:28242743
16. Zhao F, Korangy F, Greten TF. Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma. Dig Dis. 2012;30(5):477-482. https://doi.org/10.1159/000341695 PMid:23108303 PMCid:PMC3530892
17. Li E, Lin L, Chen C-W, Ou D-L. Mouse models for immunotherapy in hepatocellular carcinoma. Cancers. 2019;11(11):1800. https://doi.org/10.3390/cancers11111800 PMid:31731753 PMCid:PMC6896030
18. Bagi CM, Andresen CJ. Models of hepatocellular carcinoma and biomarker strategy. Cancers. 2010;2(3):1441-1452. https://doi.org/10.3390/cancers2031441 PMid:24281167 PMCid:PMC3837316
19. Ren Z, Chen X, Hong L, et al. Nanoparticle conjugation of ginsenoside Rg3 inhibits hepatocellular carcinoma development and metastasis. Small. 2019;16(2). https://doi.org/10.1002/smll.201905233 PMid:31814271
20. Natri HM, Wilson MA, Buetow K. Distinct molecular etiologies of male and female hepatocellular carcinoma. Cold Spring Harbor Laboratory. 2018. https://doi.org/10.1101/507939
21. Luo Y, Song L, Wang X, et al. Uncovering the mechanisms of cryptotanshinone as a therapeutic agent against hepatocellular carcinoma. Front Pharmacol. 2020;11. https://doi.org/10.3389/fphar.2020.01264 PMid:32903546 PMCid:PMC7438559
22. Qin J, Yang L, Sheng X, et al. Antitumor effects of brucine immuno-nanoparticles on hepatocellular carcinoma in vivo. Oncol Lett. 2018. https://doi.org/10.3892/ol.2018.8168
23. Schulien I, Hasselblatt P. Diethylnitrosamine-induced liver tumorigenesis in mice. Methods Cell Biol. 2020:137-152. https://doi.org/10.1016/bs.mcb.2020.08.006 PMid:33785162
24. Singh D, Singh M, Yadav E, et al. Attenuation of diethylnitrosamine (DEN) - induced hepatic cancer in experimental model of Wistar rats by Carissa carandas embedded silver nanoparticles. Biomed Pharmacother. 2018;108:757-765. https://doi.org/10.1016/j.biopha.2018.09.066 PMid:30248544
25. Singh D, Singh M, Yadav E, et al. Amelioration of diethylnitrosamine (DEN)-induced hepatocellular carcinogenesis in animal models via knockdown of oxidative stress and proinflammatory markers by Madhuca longifolia embedded silver nanoparticles. RSC Adv. 2018;8(13):6940-6953. https://doi.org/10.1039/C7RA12775H PMid:35540326 PMCid:PMC9078335
26. Singh R, Sharma J, Goyal PK. Prophylactic role of Averrhoa carambola(star fruit) extract against chemically induced hepatocellular carcinoma in swiss albino mice. Adv Pharmacol Sci. 2014:1-8. https://doi.org/10.1155/2014/158936 PMid:24696677 PMCid:PMC3950398
27. Thamer NA. Green synthesized silver nanoparticles using Crocus sativus L extract after reduces prehepatocellular carcinoma in rats. Iraqi J Cancer Med Genet. 2018;9(2). https://doi.org/10.29409/ijcmg.v9i2.191
28. Andersen JB, Loi R, Perra A, et al. Progenitor‐derived hepatocellular carcinoma model in the rat†. Hepatology. 2010;51(4):1401-1409. https://doi.org/10.1002/hep.23488 PMid:20054870 PMCid:PMC2914300
29. Shirato K, Morimoto M, Tomita N, et al. Hepatocellular carcinoma. J Ultrasound Med. 2002;21(9):1015-1022. https://doi.org/10.7863/jum.2002.21.9.1015 PMid:12216749
30. Bu L, Xie J, Chen K, et al. Assessment and comparison of magnetic nanoparticles as MRI contrast agents in a rodent model of human hepatocellular carcinoma. Contrast Media Mol Imaging. 2012;7(4):363-372. https://doi.org/10.1002/cmmi.494 PMid:22649042 PMCid:PMC3759163
31. Hu P, Fu Z, Liu G, et al. Gadolinium-based nanoparticles for theranostic MRI-guided radiosensitization in hepatocellular carcinoma. Front Bioeng Biotechnol. 2019;7. https://doi.org/10.3389/fbioe.2019.00368 PMid:31828068 PMCid:PMC6890599
32. You Y, Zhu F, Li Z, et al. Phyllanthin prevents diethylnitrosamine (DEN) induced liver carcinogenesis in rats and induces apoptotic cell death in HepG2 cells. Biomed Pharmacother. 2021;137:111335. https://doi.org/10.1016/j.biopha.2021.111335 PMid:33581648
33. Liu L, Wang B, Ma Y, et al. A review of Phyllanthus urinaria L. in the treatment of liver disease: viral hepatitis, liver fibrosis/cirrhosis and hepatocellular carcinoma. Front Pharmacol. 2024;15. https://doi.org/10.3389/fphar.2024.1443667 PMid:39185304 PMCid:PMC11341462
34. Wang J, Li C-D, Sun L. Recent advances in molecular mechanisms of the NKG2D pathway in hepatocellular carcinoma. Biomolecules. 2020;10(2):301. https://doi.org/10.3390/biom10020301 PMid:32075046 PMCid:PMC7094213
35. Liu Y, Yang Z, Du F, et al. Molecular mechanisms of pathogenesis in hepatocellular carcinoma revealed by RNA-sequencing. Mol Med Rep. 2017;16(5):6674-6682. https://doi.org/10.3892/mmr.2017.7457 PMid:28901494 PMCid:PMC5865798
36. Li Y, Hecht SS. Metabolic activation and DNA interactions of carcinogenic N-nitrosamines to which humans are commonly exposed. Int J Mol Sci. 2022;23(9):4559. https://doi.org/10.3390/ijms23094559 PMid:35562949 PMCid:PMC9105260
37. Boysen G, Pachkowski BF, Nakamura J, Swenberg JA. The formation and biological significance of N7-guanine adducts. Mutat Res Genet Toxicol Environ Mutagen. 2009;678(2):76-94. https://doi.org/10.1016/j.mrgentox.2009.05.006 PMid:19465146 PMCid:PMC2739241
38. Perrino FW, Blans P, Harvey S, et al. The N2-ethylguanine and the O6-ethyl- and O6-methylguanine lesions in DNA: contrasting responses from the "bypass" DNA polymerase η and the replicative DNA polymerase α. Chem Res Toxicol. 2003;16(12):1616-1623. https://doi.org/10.1021/tx034164f PMid:14680376
39. Nakamura YK, Omaye ST. Age-related changes of serum lipoprotein oxidation in rats. Life Sci. 2003;74(10):1265-1275. https://doi.org/10.1016/j.lfs.2003.08.007 PMid:14697409
40. Kang JS, Wanibuchi H, Morimura K, et al. Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis in vivo. Cancer Res. 2007;67(23):11141-11146. https://doi.org/10.1158/0008-5472.CAN-07-1369 PMid:18056438
41. Arboatti AS, Lambertucci F, Sedlmeier MG, et al. Diethylnitrosamine increases proliferation in early stages of hepatic carcinogenesis in insulin-treated type 1 diabetic mice. BioMed Res Int. 2018:1-10. https://doi.org/10.1155/2018/9472939 PMid:29850590 PMCid:PMC5937583
42. Takaki A. Control of oxidative stress in hepatocellular carcinoma: helpful or harmful? World J Hepatol. 2015;7(7):968. https://doi.org/10.4254/wjh.v7.i7.968 PMid:25954479 PMCid:PMC4419100
43. Zhang L, Chen C, Duanmu J, et al. Cryptotanshinone inhibits the growth and invasion of colon cancer by suppressing inflammation and tumor angiogenesis through modulating MMP/TIMP system, PI3K/Akt/mTOR signaling and HIF-1α nuclear translocation. Int Immunopharmacol. 2018;65:429-437. https://doi.org/10.1016/j.intimp.2018.10.035 PMid:30388517
44. Cordover E, Minden A. Signaling pathways downstream to receptor tyrosine kinases: targets for cancer treatment. J Cancer Metastasis Treat. 2020. https://doi.org/10.20517/2394-4722.2020.101
45. Martinez-Quetglas I, Pinyol R, Dauch D, et al. IGF2 is up-regulated by epigenetic mechanisms in hepatocellular carcinomas and is an actionable oncogene product in experimental models. Gastroenterology. 2016;151(6):1192-1205. https://doi.org/10.1053/j.gastro.2016.09.001 PMid:27614046
46. Aravalli RN, Steer CJ, Cressman ENK. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48(6):2047-2063. https://doi.org/10.1002/hep.22580 PMid:19003900
47. Liang Y, Liang Q, Qiao L, Xiao F. MicroRNAs modulate drug resistance-related mechanisms in hepatocellular carcinoma. Front Oncol. 2020;10. https://doi.org/10.3389/fonc.2020.00920 PMid:32695666 PMCid:PMC7338562
48. Qi S-X, Sun H, Liu H, et al. Role and mechanism of circ-PRKCI in hepatocellular carcinoma. World J Gastroenterol. 2019;25(16):1964-1974. https://doi.org/10.3748/wjg.v25.i16.1964 PMid:31086464 PMCid:PMC6487381
49. SRIGOPALRAM S, JAYRAAJ IA. EFFECT OF TERMINALIA CHEBULA RETZ ON DEN INDUCED HEPATOCELLULAR CARCINOGENESIS IN EXPERIMENTAL RATS. Int J Pharm Pharm Sci. 2012;4(2):440-445. https://doi.org/10.1016/j.bionut.2011.12.003
50. Krishnan GS, Rajagopal V, Joseph SRA, et al. In vitro, in silico and in vivo antitumor activity of crude methanolic extract of Tetilla dactyloidea (carter, 1869) on DEN induced HCC in a rat model. Biomed Pharmacother. 2017;95:795-807. https://doi.org/10.1016/j.biopha.2017.08.054 PMid:28892791
51. Vidya R, Kalaivani K, Amudha P. Therapeutic potential of Cucumis melo (L.) fruit extract and its silver nanopartciles against DEN-induced hepatocellular cancer in rats. Appl Biochem Biotechnol. 2021;194(1):368-381. https://doi.org/10.1007/s12010-021-03765-9 PMid:34792748
52. Cheng M, He B, Wan T, et al. 5-fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. PLoS One. 2012;7(10):e47115. https://doi.org/10.1371/journal.pone.0047115 PMid:23077553 PMCid:PMC3471936
53. Hassan SK, Mousa AM, Eshak MG, et al. Therapeutic and chemopreventive effects of nano curcumin against diethylnitrosamine induced hepatocellular carcinoma in rats. Int J Pharm Pharm Sci. 2014;6(3):54-62. http://www.ijppsjournal.com/Vol6Issue3/8477.pdf
54. Mo'men YS, Hussein RM, Kandeil MA. Involvement of PI3K/Akt pathway in the protective effect of hesperidin against a chemically induced liver cancer in rats. J Biochem Mol Toxicol. 2019;33(6). https://doi.org/10.1002/jbt.22305MPMid:30779474
55. Sarkar S, Das AK, Bhattacharya S, et al. Isorhamnetin exerts anti-tumor activity in DEN + CCl4-induced HCC mice. Med Oncol. 2023;40(7). https://doi.org/10.1007/s12032-023-02050-5 PMid:37226027
56. Chenthamara D, Subramaniam S, Ramakrishnan SG, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23(1). https://doi.org/10.1186/s40824-019-0166-x PMid:31832232 PMCid:PMC6869321
57. Metkar SP, Fernandes G, Navti PD, et al. Nanoparticle drug delivery systems in hepatocellular carcinoma: a focus on targeting strategies and therapeutic applications. OpenNano. 2023;12:100159. https://doi.org/10.1016/j.onano.2023.100159
58. Elaidy SM, Moghazy A, El-Kherbetawy MK. Evaluation of the therapeutic effects of Polyvinylpyrrolidone-Capped silver nanoparticles on the Diethylnitrosamine/Carbon Tetrachloride-Induced hepatocellular carcinoma in rats. Egypt J Basic Clin Pharmacol. 2017;7. https://doi.org/10.32527/2017/101422
59. Chugh H, Sood D, Chandra I, et al. Role of gold and silver nanoparticles in cancer nano-medicine. Artif Cells Nanomed Biotechnol. 2018;46(sup1):1210-1220. https://doi.org/10.1080/21691401.2018.1449118 PMid:29533101
60. Khaled AM, Othman MS, Obeidat ST, et al. Green-synthesized silver and selenium nanoparticles using berberine: a comparative assessment of in vitro anticancer potential on human hepatocellular carcinoma cell line (HepG2). Cells. 2024;13(3):287. https://doi.org/10.3390/cells13030287 PMid:38334679 PMCid:PMC10854975
61. Mohamed MR, Osman SA, Hassan AA, et al. Gemcitabine and synthesized silver nanoparticles impact on chemically induced hepatocellular carcinoma in male rats. Int J Immunopathol Pharmacol. 2024;38. https://doi.org/10.1177/03946320241263352 PMid:39046434 PMCid:PMC11271163
62. Uchida D, Takaki A, Oyama A, et al. Oxidative stress management in chronic liver diseases and hepatocellular carcinoma. Nutrients. 2020;12(6):1576. https://doi.org/10.3390/nu12061576 PMid:32481552 PMCid:PMC7352310
63. Kouroumalis E, Tsomidis I, Voumvouraki A. Pathogenesis of hepatocellular carcinoma: the interplay of apoptosis and autophagy. Biomedicines. 2023;11(4):1166. https://doi.org/10.3390/biomedicines11041166 PMid:37189787 PMCid:PMC10135776
64. Elmetwalli A, Abdel-Monem MO, El-Far AH, et al. Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment. Med Oncol. 2024;41(5). https://doi.org/10.1007/s12032-024-02330-8 PMid:38575697 PMCid:PMC10995097
65. Ahmadian E, Dizaj SM, Rahimpour E, et al. Effect of silver nanoparticles in the induction of apoptosis on human hepatocellular carcinoma (HepG2) cell line. Mater Sci Eng C. 2018;93:465-471. https://doi.org/10.1016/j.msec.2018.08.027 PMid:30274079
66. Tanaka S, Mogushi K, Yasen M, et al. Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: a prospective, multicenter study. Hepatology. 2011;54(4):1273-1281. https://doi.org/10.1002/hep.24536 PMid:22006857
67. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 2010;21(1):35-43. https://doi.org/10.1016/j.semcancer.2010.10.007 PMid:20946957 PMCid:PMC3050428
68. Moeini A, Cornellà H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer. 2012;1(2):83-93. https://doi.org/10.1159/000342405 PMid:24159576 PMCid:PMC3747540
69. Huang P, Xu X, Wang L, et al. The role of EGF‐EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment. J Cell Mol Med. 2013;18(2):218-230. https://doi.org/10.1111/jcmm.12153 PMid:24268047 PMCid:PMC3930409
70. Huang Q, Li J, Zheng J, Wei A. The carcinogenic role of the Notch signaling pathway in the development of hepatocellular carcinoma. J Cancer. 2019;10(6):1570-1579. https://doi.org/10.7150/jca.26847 PMid:31031867 PMCid:PMC6485212
71. Ferrín G, Guerrero M, Amado V, et al. Activation of mTOR signaling pathway in hepatocellular carcinoma. Int J Mol Sci. 2020;21(4):1266. https://doi.org/10.3390/ijms21041266 PMid:32070029 PMCid:PMC7072933
72. Jeng K, Jeng C, Jeng W, et al. Sonic hedgehog signaling pathway as a potential target to inhibit the progression of hepatocellular carcinoma (review). Oncol Lett. 2019. https://doi.org/10.3892/ol.2019.10826 PMid:31611946 PMCid:PMC6781692
73. Jia Y, Yang Y, Liu S, et al. SOX17 antagonizes WNT/β-catenin signaling pathway in hepatocellular carcinoma. Epigenetics. 2010;5(8):743-749. https://doi.org/10.4161/epi.5.8.13104 PMid:20716954
74. Wang X, Xiang L, Li H, et al. The role of HMGB1 signaling pathway in the development and progression of hepatocellular carcinoma: a review. Int J Mol Sci. 2015;16(9):22527-22540. https://doi.org/10.3390/ijms160922527 PMid:26393575 PMCid:PMC4613322
75. Kudo M. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. Dig Dis. 2011;29(3):289-302. https://doi.org/10.1159/000327562 PMid:21829020
76. YANG Z, YANG S, MISNER BJ, LIU-SMITH F, MEYSKENS FL. The role of APE/ref-1 signaling pathway in hepatocellular carcinoma progression. Int J Oncol. 2014;45(5):1820-1828. https://doi.org/10.3892/ijo.2014.2589 PMid:25109342 PMCid:PMC4735689
77. Huang X-Y, Huang Z-L, Zhang P-B, et al. CircRNA-100338 is associated with mTOR signaling pathway and poor prognosis in hepatocellular carcinoma. Front Oncol. 2019;9. https://doi.org/10.3389/fonc.2019.00392 PMid:31157168 PMCid:PMC6528706
78. Wang X, Zhang J, Zhou L, et al. Fbxw7 regulates hepatocellular carcinoma migration and invasion via Notch1 signaling pathway. Int J Oncol. 2015;47(1):231-243. https://doi.org/10.3892/ijo.2015.2981 PMid:25955618
79. Jiang J, Chen Y, Dong T, et al. Polydatin inhibits hepatocellular carcinoma via the AKT/STAT3 FOXO1 signaling pathway. Oncol Lett. 2019. https://doi.org/10.3892/ol.2019.10123
80. Li Y, Li P, Wang N. Effect of let 7c on the PI3K/Akt/FoxO signaling pathway in hepatocellular carcinoma. Oncol Lett. 2020;21(2). https://doi.org/10.3892/ol.2020.12357 PMid:33376529 PMCid:PMC7751369
81. Wang J, Tian Y, Chen H, et al. Key signaling pathways, genes and transcription factors associated with hepatocellular carcinoma. Mol Med Rep. 2018. https://doi.org/10.3892/mmr.2018.8871
82. Nie X, Liu Y, Chen W-D, Wang Y-D. Interplay of miRNAs and canonical Wnt signaling pathway in hepatocellular carcinoma. Front Pharmacol. 2018;9. https://doi.org/10.3389/fphar.2018.00657 PMid:29977206 PMCid:PMC6021530
83. Ciccarone F, Castelli S, Ciriolo MR. Oxidative stress-driven autophagy acROSs onset and therapeutic outcome in hepatocellular carcinoma. Oxid Med Cell Longev. 2019:1-10. https://doi.org/10.1155/2019/6050123 PMid:31205585 PMCid:PMC6530208
84. Shimizu Y, Tamura T, Kemmochi A, et al. Oxidative stress and liver X receptor agonist induce hepatocellular carcinoma in non‐alcoholic steatohepatitis model. J Gastroenterol Hepatol. 2020;36(3):800-810. https://doi.org/10.1111/jgh.15239 PMid:32870526 PMCid:PMC7983938
85. McLoughlin MR, Orlicky DJ, Prigge JR, et al. TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy. Proc Natl Acad Sci USA. 2019;116(23):11408-11417. https://doi.org/10.1073/pnas.1903244116 PMid:31097586 PMCid:PMC6561278
86. Duan T, Sun W, Zhang M, et al. Dietary restriction protects against diethylnitrosamine-induced hepatocellular tumorigenesis by restoring the disturbed gene expression profile. Sci Rep. 2017;7(1). https://doi.org/10.1038/srep43745 PMid:28262799 PMCid:PMC5338348
87. Hashem MA, Zidan AZM, El-Mandrawy SA. POTENTIAL PERFECTION EFFECTS OF SILVER NANOPARTICLES AGAINST CISPLATIN SIDE EFFECTS IN HEPATOCELLULAR CARCINOMA INDUCED IN SPRAGUE DAWLEY ALBINO RATS: HEMATOLOGICAL, BIOCHEMICAL, HISTOPATHOLOGICAL, AND IMMUNOHISTOCHEMICAL ALTERATIONS. Sloven Vet Res. 2023;60(25-Suppl). https://doi.org/10.26873/SVR-1554-2022
88. Petri S, Körner S, Kiaei M. Nrf2/ARE signaling pathway: key mediator in oxidative stress and potential therapeutic target in ALS. Neurol Res Int. 2012:1-7. https://doi.org/10.1155/2012/878030 PMid:23050144 PMCid:PMC3461296
89. Prasannaraj G, Venkatachalam P. Hepatoprotective effect of engineered silver nanoparticles coated bioactive compounds against diethylnitrosamine induced hepatocarcinogenesis in experimental mice. J Photochem Photobiol B. 2017;167:309-320. https://doi.org/10.1016/j.jphotobiol.2017.01.009 PMid:28129629
90. Sui C, Zhuang C, Sun D, et al. Notch1 regulates the JNK signaling pathway and increases apoptosis in hepatocellular carcinoma. Oncotarget. 2017;8(28):45837-45847. https://doi.org/10.18632/oncotarget.17434 PMid:28507277 PMCid:PMC5542231
91. HAYAKAWA R, HAYAKAWA T, TAKEDA K, ICHIJO H. Therapeutic targets in the ASK1-dependent stress signaling pathways. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(8):434-453. https://doi.org/10.2183/pjab.88.434 PMid:23060232 PMCid:PMC3491083
92. Wu X, Xie G, Chen D. Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22(8):1178-1182. https://doi.org/10.1111/j.1440-1746.2007.04997.x PMid:17559361
93. Mossenta M, Busato D, Dal Bo M, Toffoli G. Glucose metabolism and oxidative stress in hepatocellular carcinoma: role and possible implications in novel therapeutic strategies. Cancers. 2020;12(6):1668. https://doi.org/10.3390/cancers12061668 PMid:32585931 PMCid:PMC7352479
94. GAO J-Z, DU J-L, WANG Y-L, et al. Synergistic effects of curcumin and bevacizumab on cell signaling pathways in hepatocellular carcinoma. Oncol Lett. 2014;9(1):295-299. https://doi.org/10.3892/ol.2014.2694 PMid:25435978 PMCid:PMC4246621
95. Gong J, Chuang J, Cho M, et al. Molecular targets, pathways, and therapeutic implications for hepatocellular carcinoma. Int J Mol Sci. 2020;21(15):5232. https://doi.org/10.3390/ijms21155232 PMid:32718047 PMCid:PMC7432744
Published
Abstract Display: 783 
PDF Downloads: 590 PDF Downloads: 54 How to Cite
Issue
Section
Copyright (c) 2025 Rohit Gangawat, Lavina Bagoria, Shweta Ratanpal, Ritu Kamal Yadav
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.